Table 1.

Study sample demographic and clinical characteristics

CharacteristicStudy cohort (n = 75)
Sex (%)
 Male40 (53.3)
 Female35 (46.7)
Race/ethnicity (%)
 Latino/Hispanic45 (60.0)
 Caucasian/Non-Hispanic19 (25.3)
 Asian6 (8.0)
 Black/African American4 (5.3)
 Other1 (1.4)
Age at diagnosis (y)
 Median (range)7.7 (1.8–20.2)
Diagnosis
 Acute lymphoblastic leukemia23 (30.7)
 Germ cell tumor14 (18.7)
 Acute myeloid leukemia10 (13.3)
 Osteosarcoma9 (12.0)
 Ewing sarcoma7 (9.3)
 Wilms tumor4 (5.3)
 Nasopharyngeal carcinoma1 (1.4)
 Rhabdomyosarcoma7 (9.3)
Tumor resection (%)
 N/A33 (44)
 No7 (9.3)
 Yes35 (46.7)
HSCT (%)
 No71 (94.7)
 Yes4 (5.3)
PRBC transfusions (%)
 No8 (10.7)
 Yes67 (89.3)
  <10 PRBC transfusions31 (41.3)
  ≥10 PRBC transfusions36 (48)
Cumulative PRBC volume (mL)
 Median (range)2,084 (0–14,224)
Adjusted cumulative PRBC volume (mL/kg)
 Median (range)71.7 (0–391.9)
Projected total iron burden (mg)
 Median (range)1,437 (0–9,383)
Projected liver iron content (mg/g liver, dry weight)
 Median (range)1.2 (0.9–23.7)
Treatment intensity (levels) by ITR-3 rating (%)
 Least intensive–moderately intensive39 (52)
 Very intensive22 (29.3)
 Most intensive14 (18.7)
Age at study evaluation (y)
 Median (range)14 (8–25.6)
Follow-up time at study evaluation (y)
 Median (range)4.4 (0.2–7.6)
Time since last transfusion (y)
 Median (range)4.9 (1.4–7.9)
Hemochromatosis mutation status at study evaluation
 C282Y homozygous mutations0
 H63D–C282Y compound mutations0